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ABSTRACT 
Breast cancer (BC) is the most frequent tumor worldwide. Triple-negative BCs are characterized by the negative estrogen and 
progesterone receptors and negative HER2, and represent 12-18%  of all BCs.Breast cancer (breast cancer) is the most common 
oncological disease in women in the Uzbekistan. Data from epidemiological studies show that TNBC is more common in young 
women (up to 50 years) before menopause. In addition, the likelihood of TNBC is higher in women with early menarche, the first 
pregnancy at an earlier age, a short period of breastfeeding, and an increased body mass index. It should be not that the prognosis for 
TNBC does not depend on the degree of differentiation of the tumor, the presence of lymph node metastases, the size of the tumor or 
the treatment performed. The aggressiveness of TNBC was also confirmed by the maximum risk of recurrence during the first three 
years after surgical treatment with a maximum mortality within the first 5 years. TNBC is a subtype of tumors with a special 
character of metastasis. Based on the above, we have undertaken the present work, having set ourselves the following goal: to 
improve immediate and long-term results of treatment of patients with locally advanced thyroid cancer by using the most effective 
diagnostic methods and comprehensive treatment.  
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INTRODUCTION 
Triple-negative breast cancers have a relapse pattern that 
is very different from hormone-positive breast cancers: 
the risk of relapse is much higher for the first 3–5 years 
but drops sharply and substantially below after those 
hormone-positive breast cancers. In this review, data on 
the use of gemsitabini in metastatic triple-negative BCs 
are analyzed, concluding they are effective in any 
clinical setting (neoadjuvant, adjuvant, and metastatic). 
The available data show the clinical potential of based 
combinations in terms of long-duration response, 
increased survival, and better quality of life of patients 
with triple-negative metastatic BC. The ongoing trials 
will give further information on the better management 
of this type of tumor.In 2016, 1,380,000 new cases and 
458,000 deaths for BC were reported worldwide, of 
which there were 332,000 new cases and 79,000 deaths 
in Asia 
1,4
.  
BC in the territory of the Republic among urban and 
rural population by determining the average annual 
intensive and standardized incidence rates for the years 
2008-2010. The highest standardized incidence rates 
registered in Tashkent city (22,5%x>00), Navaiy 
(12,4%00), Bukhara (11,1%00) and Tashkent regions 
(11,0%00) and lowest in Surkhandarya (6,3%00) and 
Kashkadarya (7,5%00). On the territory of the Republic 
those in urban areas more often suffer from cancer of the 
breast (13,2%x>00) than rural (8,5%00)
2, 3
.  
The highest incidence was within the age intervals 50-59 
- 18,0%00, 60-69 - 31,2%00, 70 years and older -
19,3%00. In the structure of mortality of the female 
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population of Uzfrom malignant neoplasmsThe greatest 
proportion is malignant breast tumors (20.4%) 
3, 6
. 
According to Cancer Registry of the Republican 
Oncology scientific center (RONTS), in 2012 in the 
general structure ofcancer of malignant neoplasms of 
women forpatients with breast cancer (24.6%) occupy 
the 1st ranked place,ahead of patients with cervical 
cancer (12.4%), (5.9%), ovaries (5.0%) and the uterus 
body (4.4%) 
7,8
. According to the Ministry of Health of 
Uzbekistan, the most common cancer in the country is 
breast cancer.This type of cancer is diagnosed in 9.1 
cases per 100 thousand of the population.According to 
experts, the hereditary factor is important in the 
development of breast cancer in women; it is on the 
maternal line. It is transmitted in 45-75% of cases, if 
there are mutations of BRSA 1-2 genes. To prevent 
breast cancer, women under the age of 50 years should 
undergo ultrasound of the breast. Women aged 50 years 
and older should undergo mammogram of the breast. 
Also, all the representatives of the fair sex need to 
conduct self-examination of the breast every month. At 
any suspicion of the presence of compaction in the 
mammary glands, consultation of a mammologist is 
necessary, noted in the Ministry of Health%) 
4, 5, 8
.  
Despite the improvement of the methods of diagnosing 
this pathology, more than 50% of primary patients 
annually turn to the oncologist in the III and IV stages of 
the disease. 
Purpose of the study is to evaluate the effectiveness of 
various chemotherapy regimens for neoadjuvant, 
adjuvant and palliative polychemotherapy (metastatic) in 
patients triple negative breast cancer with improved 
long-term treatment outcomes. 
MATERIALS AND METHODS 
The object of our study will be patients with breast 
cancer with a triple negative phenotype. In total, 
retrospective and prospective groups of patients treated 
in 2012-2017 will be studied. in Tashkent City oncology 
in the department of oncology and chemotherapy (n = 
99), patients with triple negative breast cancer. Thus, the 
patients included in the study were characterized by a set 
of unfavorable signs: in 93% of cases the tumors were 
characterized by high Ki-67, in 53%- 87.7% of cases - 
by II-IV grade of malignancy. Criteria for selecting 
patients: Progression of breast cancer was detected in the 
period from 12 to 60 months after the operative removal 
of the primary tumor (metachronous metastases); ECOG 
0-1. The age of patients older than 18 years. The 
presence of the result of immunohistochemical analysis 
of the primary tumor, and in the experimental group a 
comparative analysis of the primary tumor and distant 
metastases. Functional status according to ECOG (FS) 
was from 0 to 2. All patients had measurable normal 
kidney and liver function, satisfactory parameters of 
general and biochemical blood tests (leukocytes> 4.5 x 
109 / L, neutrophily> 2.0 x 109 / L, hemoglobin> 9 g / 
dL, blood transfusions were not tolerated for the last two 
weeks, platelets> 100 x 109 / L, creatinine <130 μmol / 
L, total bilirubin <1.5 of the upper limit of normal 
(CGI), ALT and ACT <1.5 VGN.After randomization, 
patients in a 2: 1 ratio were included in two treatment 
groups: 1) chemotherapy with doxorbicin, and/or 2) 
chemotherapy with platinum drugs. As chemotherapy, 
the following options were used: taxanes (docetaxel or 
paclitaxel), platinum, anthracyclines, gemcitabine, 
doxorubicin, cyclophosphani, capecitabine. 
RESULTS 
The triple-negative BCs (TNBCs) 
The most important biological markers, not only for 
classification of BC but also for, the therapeutic strategy 
are the hormonal receptors (estrogen [ER] and 
progesterone [PgR] receptor) and the HER2 receptor 
status 
5
. Tumors that are ER-, PgR-, and HER2-negative 
are known as TNBC and account for about 12-20% of 
BCs 
4
. These tumors develop earlier in life, especially in 
premenopausal women, and have a poorer prognosis 
than the other types of BC due to the higher 
aggressiveness. These factors may be a major reason for 
the high-risk relapse, and shorter progression-free 
survival (PFS) and overall survival (OS) reported for 
this disease 
3–6
. The main general characteristics of 
TNBC are summarized in Table 1. 
 
Table 1: General characteristics of TNBC 
• Weak association between tumor size and lymph node involvement 
• Quick growth and tissular density similar to normal tissue 
• High expression of BRCA1 mutation 
• High risk of early relapse 
• Peak recurrence between the first and third years after diagnosis 
• Metastases are rarely preceded by local recurrence 
• Higher incidence in younger women, Afro American or Hispanic, and in low socioeconomic conditions 
• Strongerassociationwithobesity 
• Higher incidence of brain metastases 
• Most deaths occur in the first 5 years 
• Rapid progression from the onset of metastasis to death 
TNBC is not a unique clinical entity. It comprises several types of cancers now characterized by molecular profiles, which represent 
different diseases with probably different treatment options and different response to chemotherapy, biological agents, and/or other 
therapeutic regimens. 
The gene expression assay classifies BCs into at least 
five groups, including luminal A, luminal B, HER2-
enriched, basal-like (BL), and normal breast-like. More 
recent gene expression array analysis has identified six 
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different groups of TNBC, including two BLs (BL1 and 
BL2), an immune-modulatory (IM), a mesenchymal 
(M), a mesenchymal stem-like (MSL), and a luminal 
androgen receptor (LAR) subtype
11, 12
. BC subtypes 
array, 25% of relapses was basal, 32% HER2, 10% 
luminal A, 28% luminal B, and 5% normal breast-like. 
Importantly, the intrinsic subtype at relapse was 
significantly associated with postrelapse survival 
(P=0.012). At the 2016 on 1,100 women diagnosed in 
2016 with TNBC in the Uzbekistan. This population 
reflects the current clinical practice in the Uzbekistan at 
the time: 34% were at stage I, 42% at stage II, 15% at 
stage III, and 6% at stage IV, with a 24-month OS of 
97%, 93%, 71%, and 27%, respectively. The median OS 
in metastatic disease was 13 months
7-10
. 
The treatment of TNBCs 
A proportion of TNBC is highly sensitive to 
chemotherapy but with a short PFS and a lower OS 
15
. 
Current therapeutic strategies include chemotherapeutic 
drugs (anthracyclines, taxanes, platinum derivatives, and 
gemsitabine) and biological drug 
11, 16
. The efficacy of 
anthracyclines and gemsitabine in metastatic BC is 
higher in ER-negative tumors; for this reason, both 
classes are indicated as first-line treatment of TNBC, 
even if with a short-lasting benefit
14
. Another group of 
drugs with proven activity in TNBC are the platinum 
derivatives cisplatin and carboplatin 
13–16
. 
Guidelines for the treatment of TNBCs 
There are no specific guidelines for the management of 
TNBC: the National Comprehensive Cancer Network 
(NCCN), European Society for Medical Oncology 
(ESMO), and AssociazioneItaliana di OncologiaMedica 
(AIOM) Guidelines recommend that TNBC be treated 
with chemotherapy (monotherapy or combination 
therapy) but do not specify the most appropriate drugs. 
Taxanes and their combinations recommended by 
NCCN, ESMO, and AIOM guidelines for triple-
negative BC 
  
Table 2: Taxanes and their combinations recommendations by NCCN, ESMO, and AIOM guidelines for TNBC 
NCCN ESMO AIOM 
Monotherapy Monotherapy (without extensive visceral 
involvement/symptomatic) 
Monotherapy 
Paclitaxel 
Docetaxel 
Nab-paclitaxel 
Weekly paclitaxel 
Weekly docetaxel or q3w 
Nab-paclitaxel 
Paclitaxel 
Docetaxel 
Nab-paclitaxel 
Combinations Combinations (with extensive visceral 
involvement/symptomatic) 
Combinations 
Docetaxel+ capecitabine 
Gemcitabine+ paclitaxel 
Paclitaxel+bevacizumab 
Anthracycline+taxane(paclitaxel ordocetaxel) 
Docetaxel + capecitabine 
Paclitaxel+gemcitabine 
Paclitaxel+vinorelbine 
Paclitaxel + carboplatin 
Anthracycline+ taxane 
(paclitaxel or docetaxel) 
Docetaxel + capecitabine 
Paclitaxel + gemcitabine 
Docetaxel + gemcitabine 
Paclitaxel + bevacizumab 
Abbreviations: AIOM, AssociazioneItaliana di OncologiaMedica; ESMO, European Society for Medical Oncology; NCCN, 
National Comprehensive Cancer Network; q3w, every 3 weeks; BC, breast cancer; TNBC, Triple Negative Breast Cancer 
The ESMO Guidelines states that cytotoxic 
chemotherapy is the standard of care for the treatment of 
TNBC and that the choice of the regimen should be 
made after consideration of disease-related factors 
(disease-free survival [DFS], previous therapies and 
response, tumor burden, and need for rapid 
disease/symptom control) and patient-related factors 
(patient preferences, biological age, menopausal status, 
comorbidities and performance status, and 
socioeconomic and psychological factors). Combination 
chemotherapy is more often required because of 
frequent visceral involvement, aggressive course, and 
risk of rapid patient deterioration. Finally, there is no a 
standard approach for chemotherapy after first line 
16,17
. 
The role of taxanes in TNBC 
The role of taxanes in TNBC is well established after 
the many studies evaluating the efficacy of taxane-based 
regimens in neoadjuvant, adjuvant, and metastatic 
disease settings. Neoadjuvant therapy has been used for 
a long time for reducing the size and the extension of 
locally advanced tumors, but now it is extensively used 
also in early BC not suitable for primary conservative 
surgery, with an added predictive value for the long-
term outcome of the disease. Actually the best efficacy 
target for neoadjuvant therapy is expressed as 
pathological complete response (pCR). The predictive 
value of pCR as a surrogate for long-term clinical 
benefit has been recently confirmed by the retrospective 
pooled analysis of Cortazar et al 
18
. This meta-analysis 
was based on the pCR, overall response rate (ORR), and 
event-free survival (EFS) data of 12 international 
clinical trials on a total 11,550 patients. The analysis 
compared the three main definitions of pCR in order to 
establish their association with long-term efficacy: ypT0 
ypN0 (no invasive and in situ tumor in the breast and 
auxiliary lymph nodes); ypT0/is ypN0 (no invasive 
tumor in the breast and axiliary lymph nodes, 
independent of the presence of in situ ductal carcinoma); 
and ypT0/is ypN0/is (no invasive tumor in the breast, 
independent of the presence of in situ ductal carcinoma 
or lymph nodes involvement). The better combination 
between pCR and long-term effect was observed in 
patients with an aggressive tumor (TNBC; high-grade; 
ER/PgR-positive, HER2-negative; HER2-positive; and 
ER- and PgR-negative) 
19
. 
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Several studies on neoadjuvant therapy confirmed the 
sensitivity of TNBC to cytotoxic drugs, as well as the 
importance of platinium-based chemotherapy. Rouzier 
et al evaluated the molecular-based chemosensitivity 
patients treated with carboplatin and taxanes 
neoadjuvant therapy, and a pCR was observed in 45% of 
BL tumors and in 6% of luminal tumors (A and B).
20-21
. 
The study evaluated in 53 women randomized to 
neoadjuvant doxorubicin and docetaxel for four cycles 
or doxorubicin and cyclophosphamide (AC) for four 
cycles followed by docetaxel for four cycles. The 
overall was 10.6% (7% with the two-drug regimen and 
14.3% with the triplet one). The efficacy of taxane-
based neoadjuvant therapy was further confirmed by 
more recent trials. Wu et al evaluated the efficacy of 
neoadjuvant therapy with docetaxel plus epirubicin, and 
the OS in 64 patients with TNBC and in 65 patients with 
non-TNBC. A pCR was observed in 25.9% of TNBCs, 
significantly higher than in the other subtypes (P=0.019) 
24
. 
The New England Journal of Medicine published a 
report by Bear et al of another trial of neoadjuvant 
chemotherapy with or without carboplatini. This Phase 
III randomized trial assigned 46 patients with HER2-
negative BC to receive docetaxel (100 mg/m
2
 every 21 
days) or docetaxel (75 mg/m
2
 day 1) plus capecitabine 
(825 mg/m
2
 twice a day days 1 to 14) or docetaxel (75 
mg/m
2
 day 1) plus gemcitabine (1,000 mg/m
2
 days 1 and 
8) for four cycles. All regimens were followed by AC 
for a further four cycles. All patients were also 
randomized to receive carboplatini (AUC=5) or not for 
the first six cycles of chemotherapy. Results showed 
first of all that the addition of carboplatiniand 
gemcitabine did not improve the rate ofdocetaxel alone 
and showed increased toxicity and that the toxicity of 
carboplatini was manageable and as expected from 
previous trials and, significantly increased the overall 
pCR rate (34.5% vs 28.2%) (P=0.02). The multiple 
logistic regression model showed that TNBC subtype, 
high grade, and smaller tumor size were associated with 
higher rates in the breast, but when considering the 
breast and nodes, the addition of carboplatiniwas 
significantly related to a better result in hormone 
receptor-positive tumors only. 
In the randomized 45 patients with TNBC were treated 
with weekly paclitaxel plus liposomal doxorubicin (once 
a week for 18 weeks) every 3 weeks and were 
randomized to receive weekly carboplatin (area under 
the time–concentration curve [AUC] =2) or not. The 
pCR (ypT0ypN0) rate was 16% higher with the addition 
of carboplatin (53.2% vs 36.9%) (P=0.005). The toxicity 
was also significantly higher, with 53% discontinuation 
(41% with AUC reduced to 1.5). Data on the BRCA 
mutation are not yet available in order to assess the 
correct role of carboplatin 
18,19
. 
The adjuvant setting 
Studies in adjuvant setting also confirmed the activity 
and relevance of taxanes in TNBCs. Hayes et al 
retrospectively analyzed the histological samples of 52 
patients enrolled in the study in order to evaluate the 
role of HER2 status on clinical end points. Patients were 
divided in four groups: endocrine receptor- and HER2-
negative (TNBC); endocrine receptor- and HER2-
positive; endocrine receptor-positive and HER2-
negative; endocrine receptor-negative and HER2-
positive. Adding taxanes/cyclophosphani 
withanthracycline improved DFS both in HER2-positive 
patients, independently from endocrine receptor status, 
and in TNBC patients. No clinical benefit was observed 
in HER2-negative and endocrine receptor-positive 
tumors. This explorative analysis suggests that 
paclitaxel added to the adjuvant regimen significantly 
improves the outcome in TNBCs 
20,21,22
. 
The study of conducted on 52 patients, evaluated in the 
adjuvant setting the efficacy of AC followed by weekly 
or 3-weekly (q3w) docetaxel or paclitaxel. The results 
showed an improvement both in DFS and 5-year OS 
with weekly paclitaxel with respect to q3w paclitaxel. In 
TNBCs, the benefit of conventional weekly paclitaxel in 
term of DFS was 37% higher than the q3w regimen 
23,24,26
. 
The metastatic setting 
Conventional gemsitabine have a central role in the 
treatment of metastatic BC, based on several evidences 
of their benefits on clinical outcomes, such as OS, time 
to progression (TTP) 
25,26
. 
Even if conventional gemsitabine demonstrated to be 
more active in endocrine receptor-negative tumors and 
are indicated in the first-line treatment of TNBC 
(although a specific benefit in this setting was not 
observed), it should be considered that they are 
commonly used in adjuvant therapy and cannot be 
rechallenged in case of short disease-free interval (<12 
months). 
Fan et al evaluated the efficacy of gemsitabine 
combined with cisplatin or capecitabinewith docetaxelin 
the first-line treatment of patients with metastatic TNBC 
27
. The ORR was significantly higher in patients treated 
with gemsitabine plus cisplatin than with docetaxel plus 
capecitabine (63% vs 15.4%) (P=0.001), as were the 
median PFS (10.9 vs 4.8 months) (P<0.001) and median 
OS (32.8 vs 21.5 months) (P=0.027), confirming the 
role of platinum in TNBC 
29
. 
The TNBC trial was based on the hypothesis that 
because BRCA1/2germline mutations produce BCs that 
have defects in homologous recombination DNA repair, 
carboplatin would be lethal to cells with germline and 
somatic mutations in BRCA1/2. In other words, 
carboplatin might be an especially good therapy in terms 
of exploiting the defect in homologous recombination 
DNA repair, and this is why patients with BRCA1/2 
mutations were included with TNBC patients. The 
results showed no significant difference in response 
rates between carboplatin and gemsitabini in the overall 
patient group or in patients who received either agent as 
first-line therapy and then crossed over to the other 
agent as second-line treatment 
28,30
. 
In conclusion, the main reason of failure in metastatic 
BC is resistance to the standard drugs, which can be 
intrinsic or acquired. Patients with disease progression 
or resistance could not have a cross-resistance with other 
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drugs, such as capecitabine, gemcitabine, which 
demonstrated their efficacy in patients with advanced 
BC pretreated with carboplatini with gemsitabin. 
CONCLUSION 
TNBC is characterized by the absence of ER-, PgR-, and 
HER2-negativity: for this reason the only therapeutic 
option is chemotherapy. Even if these tumors are 
chemosensitive, as showed by the high pCR obtained 
with neoadjuvant therapy, metastatic patients have a 
short PFS; this the chemosensitivity does not translate in 
an improvement of PFS or OS, and the overall prognosis 
for these tumors is poor.The studies performed taxanes 
with platinium based chemotherapy demonstrated their 
efficacy in the treatment of TNBC in by setting 
neoadjuvant, and cyclophosphan with doxorubisin or 
doxetaxel more effectively in adjuvant regimens, 
gemsitabines with platinium was detected more 
metastatic triple negative breast cancer, international 
and national guidelines recommend the as possible 
active first-line therapeutic options for TNBC. 
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